Compreendendo a origem dos paragangliomas
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: Os paragangliomas são tumores neuroendócrinos raros e de crescimento lento, frequentemente agrupados com os feocromocitomas devido às suas semelhanças celulares. Eles surgem a partir de células da crista neural e podem ser encontrados dentro dos sistemas nervosos simpático ou parassimpático, com apresentações clínicas variadas, dependendo da sua localização e funcionalidade.
Objetivo: Elaborar ampla revisão sobre paragangliomas no contexto da neurocirurgia.
Método: A revisão utilizou as bases PubMed, Scopus e Web of Science. Foram incluídos estudos sobre epidemiologia, fisiopatologia, características genéticas e manifestações clínicas. Os critérios de inclusão abrangeram estudos clínicos, revisões sistemáticas e estudos de caso publicados entre 2000 e 2023. A análise foi focada nos aspectos neurocirúrgicos do tratamento, riscos associados e os avanços no diagnóstico e manejo dessas neoplasias.
Resultado: Foram incluídos 68 artigos que focaram o tema referido nesta revisão.
Conclusão: Apesar de serem predominantemente benignos, aproximadamente 10% apresentam comportamento maligno. Sua natureza altamente vascularizada e a proximidade com estruturas neurovasculares críticas apresentam desafios cirúrgicos. O teste genético, especialmente para mutações no gene SDH, desempenha papel importante para o direcionamento do manejo e na avaliação do risco de malignidade.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and Genetics of Tumours of the Endocrine Organs. WHO Classification of Tumours. Lyon: IARC Press; 2004.
Basel H, Bozan N. Open-access Paragangliomas cervicais: experiência de 114 casos em 14 anos. 2021;87(2):127-13. https://doi.org/10.1016/j.bjorl.2018.05.001
Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, et al. Genetics, diagnosis, management, and research directions of pheochromocytoma and paraganglioma: a statement and consensus of the Endocrine Hypertension Working Group of the European Society of Hypertension. J Hypertens. 2020;38(8):1443-56. https://doi.org/10.1097/hjh.0000000000002438
Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JWM, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1–G10. https://doi.org/10.1530/eje-16-0033
Lloyd S, Obholzer R, Tysome J. British Skull Base Society Consensus Document on the Management of Head and Neck Paragangliomas. Otolaryngol Head Neck Surg. 2020;163(3):400-9. https://doi.org/10.1177/0194599820915490
Williams MD, Tischler AS. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas. Head Neck Pathol. 2017;11(1):88–95. https://doi.org/10.1007/s12105-017-0786-1
Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2011;18:R253-76. https://doi.org/10.1530/erc-11-0170
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol. 2013;20:1444-50. https://doi.org/10.1245/s10434-013-2942-5
Laird AM, Gauger PG, Doherty GM, Miller BS. Paraganglioma: not just an extra-adrenal pheochromocytoma. Langenbecks Arch Surg. 2012;397:247-53. https://doi.org/10.1007/s00423-011-0871-y
Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552-65. https://doi.org/10.1056/nejmra1806651
van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH, van de Kamp JJ. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet. 1989;2:1291-4. https://doi.org/10.1016/s0140-6736(89)91908-9
Aluko OA, Ruby E. Paraganglioma. J Endocr Soc. 2021;5(Suppl 1):A596–A597. https://doi.org/10.1210/jendso/bvab048.1216
Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in non-syndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459-66. https://doi.org/10.1056/nejmoa020152
Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2017;102:1122-32. https://doi.org/10.1210/jc.2016-3829
Freier DT, Tanque ES, Harrison TS. Pediatric and adult pheochromocytomas: a biochemical and clinical comparison. Arch Surg. 1973;107:252-5. https://doi.org/10.1001/archsurg.1973.01350200114024
Hensen EF, Siemers MD, Jansen JC, Corssmit EPM, Romijn JA, Tops CMJ, et al. Mutations in SDHD are the major determinants of the clinical characteristics of Dutch head and neck paraganglioma patients. Clin Endocrinol (Oxf). 2011;75(5):650-5. https://doi.org/10.1111/j.1365-2265.2011.04097.x
Jiménez C, Cote G, Arnold A, Gagel RF. Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab. 2006;91:2851-8. https://doi.org/10.1210/jc.2005-2178
Bayley JP, Kunst HP, Cascon A, Sampietro ML, Gaal J, Korpershoek E, et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol. 2010;11(4):366-72. https://doi.org/10.1016/s1470-2045(10)70007-3
Cerecer-Gil NY, Figuera LE, Llamas FJ, Lara M, Escamilla JG, Ramos R, et al. Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. Clin Cancer Res. 2010;16(16):4148-53. https://doi.org/10.1158/1078-0432.ccr-10-0637
Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf). 2008;69(4):587-96. https://doi.org/10.1111/j.1365-2265.2008.03274.x
Venkatesan AM, Trivedi H, Adams KT, Kebebew E, Pacak K, Hughes MS. Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. Surgery. 2011;150(6):1186-93. https://doi.org/10.1016/j.surg.2011.09.026
Foo SH, Chan SP, Ananda V, Rajasingam V. Dopamine-secreting phaeochromocytomas and paragangliomas: clinical features and management. Singapore Med J. 2010;51:e89-93.
Burnichon N, Brière JJ, Libé R, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19(15):3011-20. https://doi.org/10.1093/hmg/ddq206
Korpershoek E, Favier J, Gaal J, et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472-6. https://doi.org/10.1210/jc.2011-1043
Kehrer-Sawatzki H, Cooper DN. Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes? J Med Genet. 2008;45(10):622-8. https://doi.org/10.1136/jmg.2008.059329
Nielsen SM, Rubinstein WS, Thull DL, Armstrong MJ, Feingold E, Stang MT, et al. Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. Am J Med Genet A. 2011;155A:168-73. https://doi.org/10.1002/ajmg.a.33760
Stratakis CA, Carney JA. The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009;266(1):43-52. https://doi.org/10.1111/j.1365-2796.2009.02110.x
Pasini B, McWhinney SR, Bei T, Matyakhin L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79-88. https://doi.org/10.1038/sj.ejhg.5201904
Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108(1):314-8. https://doi.org/10.1073/pnas.1009199108
Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Letón R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011;43:663-7. https://doi.org/10.1038/ng.861
Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-6. https://doi.org/10.1210/jcem.86.11.8034
Ramlawi B, David EA, Kim MP, Garcia-Morales LJ, Blackmon SH, Rice DC, et al. Contemporary surgical management of cardiac paragangliomas. Ann Thorac Surg. 2012;93(6):1972-6. https://doi.org/10.1016/j.athoracsur.2012.02.040
Brown ML, Zayas GE, Abel MD, Young-Jr WF, Schaff HV. Mediastinal paragangliomas: the mayo clinic experience. Ann Thorac Surg. 2008;86(3):946-51. https://doi.org/10.1016/j.athoracsur.2008.04.105
Armstrong MJ, Chiosea SI, Carty SE, Hodak SP, Yip L. Thyroid paragangliomas are locally aggressive. Thyroid. 2012;22(1):88-93. https://doi.org/10.1089/thy.2011.0110
Castelblanco E, Gallel P, Ros S, Gatius S, Valls J, De-Cubas AA, et al. Thyroid paraganglioma. Report of 3 cases and description of an immunohistochemical profile useful in the differential diagnosis with medullary thyroid carcinoma, based on complementary DNA array results. Hum Pathol. 2012;43(7):1103-12. https://doi.org/10.1016/j.humpath.2011.08.022
Simpson LN, Hughes BD, Karikari IO, Mehta AI, Hodges TR, Cummings TJ, et al. Catecholamine-secreting paraganglioma of the thoracic spinal column: report of an unusual case and review of the literature. Neurosurgery. 2012;70(4):E1049-52. https://doi.org/10.1227/neu.0b013e31822e5aae
Matsumoto M, Abe K, Baba H, Kinoshita N, Yamauchi T, Shiraishi M, et al. Paraganglioma of the cauda equina: a report of two cases with unusual histopathological features. Clin Neuropathol. 2012;31(1):39-43. Paraganglioma of the cauda equina: a report of two cases with unusual histopathological features
Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012;2012:872713. https://doi.org/10.1155/2012/872713
Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775-83. https://doi.org/10.1097/mpa.0b013e3181ebb4f0
Gimenez-Roqueplo AP, Dahia PL, Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res. 2012;44(5):328-33. https://doi.org/10.1055/s-0031-1301302
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14(3):569-85. https://doi.org/10.1677/erc-07-0074
Lee JA, Duh QY. Sporadic paraganglioma. World J Surg. 2008;32(5):683-7. https://doi.org/10.1007/s00268-007-9360-4
Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700-8. https://doi.org/10.1093/jnci/djs188
Timmers HJ, Kozupa A, Chen CC, Carrasquilo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262-9. https://doi.org/10.1200/jco.2006.09.6297
Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30(5):689-94. https://doi.org/10.1007/s00259-003-1115-3
Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39(7):1144-53. https://doi.org/10.1007/s00259-012-2087-y
Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500-16. https://doi.org/10.1148/rg.352140164
Eisenhofer G, Pamporaki C, Lenders JWM. Biochemical assessment of pheochromocytoma and paraganglioma. Endocr Rev. 2023;44(5):862-909. https://doi.org/10.1210/endrev/bnad011
Rao AB, Koeller KK, Adair CF. From the archives of the AFIP. Paragangliomas of the head and neck: radiologic-pathologic correlation. Radiographics. 1999;19(6):1605-32. https://doi.org/10.1148/radiographics.19.6.g99no251605
Miller RB, Boon MS, Atkins JP, Lowry LD. Vagal paraganglioma: the Jefferson experience. Otolaryngol Head Neck Surg. 2000;122(4):482-7. https://doi.org/10.1067/mhn.2000.102807
Stoeckli SJ, Schuknecht B, Alkadhi H, Fisch U. Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography. Laryngoscope. 2002;112(1):143-6. https://doi.org/10.1097/00005537-200201000-00025
Boedeker CC. Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2011;10:Doc03. https://doi.org/10.3205/cto000076
Bessell-Browne R, O'Malley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. AJR Am J Roentgenol. 2007;188(4):970-4. https://doi.org/10.2214/ajr.06.0827
Mukherjee JJ, Peppercorn PD, Reznek RH, Vatel V, Kaltsas G, Besser M, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels. Radiology. 1997;202(1):227-31. https://doi.org/10.1148/radiology.202.1.8988215
Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. https://doi.org/10.1210/jc.2014-1498
Wong MY, Andrews KA, Challis BG, Park SM, Acerini CL, Maher ER, et al. Clinical practice guidance: Surveillance for pheochromocytoma and paraganglioma in pediatric patients with SDHx mutations. Clin Endocrinol (Oxf). 2019;90:499–505. https://doi.org/10.1111/cen.13926
Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM, et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. J Clin Endocrinol Metab. 2017;102(4):1122-32. https://doi.org/10.1210/jc.2016-3829